Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curis LifesciencesNSE:CURIS +2.79%19 Days Payable is 61.53 as of Mar. 2026, which is 43% below its 10-year median of 107.84. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 927 Drug Manufacturers companies, Curis Lifesciences ranks worse than 67.1% on this metric.
The historical rank and industry rank for Curis Lifesciences's Days Payable or its related term are showing as below:
NSE:CURIS'
s Days Payable Range Over the Past 10 Years
Min: 61.53 Med: 107.84 Max: 142.93
Current: 61.53
During the past 4 years, Curis Lifesciences's highest Days Payable was 142.93. The lowest was 61.53. And the median was 107.84.
NSE:CURIS's Days Payable is ranked worse than 67.1% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs NSE:CURIS: 61.53
Curis Lifesciences's Days Payable
declined
from Mar. 2024 (142.08) to Mar. 2026 (61.53).
It may suggest that Curis Lifesciencesaccelerated paying its suppliers.
Curis Lifesciences Days Payable Related Terms
Curis Lifesciences Days Payable Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences Days Payable Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Days Payable
142.93
142.08
73.59
61.53
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
Days Payable
142.93
142.08
73.59
61.53
NSE:CURIS vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Curis Lifesciences's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences (NSE:CURIS) has a Days Payable of 61.53 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Curis Lifesciences and its competitors. This is 43% below median its historical median of 107.84. Over the past decade, Curis Lifesciences' Days Payable has ranged from 61.53 to 142.93. According to the industry distribution chart, Curis Lifesciences ranks #622 out of 927 companies in the Drug Manufacturers industry, placing it in the top 67.1%.
Is Curis Lifesciences' Days Payable too high?
Curis Lifesciences' current Days Payable of 61.53 is 43% below median its 10-year median of 107.84. Over the past 10 years, this metric has ranged from a low of 61.53 to a high of 142.93. The Drug Manufacturers industry median Days Payable is 90.38. Curis Lifesciences' value of 61.53 is 31.9% below this industry median. Based on the distribution chart, Curis Lifesciences ranks #622 out of 927 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #622 out of 927 companies for Days Payable. This places Curis Lifesciences in the lower half of its industry. The industry median Days Payable is 90.38. Curis Lifesciences' value of 61.53 is 31.9% below this benchmark. Historically, Curis Lifesciences' own Days Payable has ranged from 61.53 to 142.93 over the past decade. While the company's 10-year median is 107.84 vs. the industry median of 90.38, Curis Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current Days Payable of 61.53 is 31.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current Days Payable is 61.53, which is 43% below median its own 10-year median of 107.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current Days Payable of 61.53. The current Days Payable is 61.53, which is 43% below median its 10-year median of 107.84 and 31.9% below the Drug Manufacturers industry median of 90.38. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current Days Payable is 61.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score
Get the complete analysis for NSE:CURIS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 
